Abera Bioscience AB (NGM:ABERA)
Sweden
· Delayed Price · Currency is SEK 6.00
-0.10 (-1.64%)
At close: Mar 9, 2026
Abera Bioscience AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Cash & Equivalents | 23.49 | 6.09 | 3.32 | 15.43 | 11.95 | Upgrade
|
| Cash & Short-Term Investments | 23.49 | 6.09 | 3.32 | 15.43 | 11.95 | Upgrade
|
| Cash Growth | 285.70% | 83.49% | -78.50% | 29.13% | 1224.40% | Upgrade
|
| Other Receivables | 0.99 | 0.65 | 0.77 | 0.77 | 0.3 | Upgrade
|
| Receivables | 0.99 | 0.65 | 0.77 | 0.77 | 0.3 | Upgrade
|
| Prepaid Expenses | 0.9 | 3.91 | 3.38 | 1.49 | 0.19 | Upgrade
|
| Other Current Assets | - | - | - | -0 | - | Upgrade
|
| Total Current Assets | 25.37 | 10.65 | 7.46 | 17.69 | 12.44 | Upgrade
|
| Property, Plant & Equipment | 1.3 | 1.07 | - | - | - | Upgrade
|
| Long-Term Deferred Charges | 1.89 | 1.89 | 1.89 | 1.89 | 1.89 | Upgrade
|
| Other Long-Term Assets | - | -0 | - | - | 17.05 | Upgrade
|
| Total Assets | 28.57 | 13.6 | 9.35 | 19.57 | 31.37 | Upgrade
|
| Accounts Payable | 1.53 | 1.23 | 2.2 | 1.67 | 0.99 | Upgrade
|
| Accrued Expenses | 0.84 | 0.95 | 1.23 | 0.97 | 1.17 | Upgrade
|
| Other Current Liabilities | 6.91 | 2.77 | 0.27 | 0.16 | 0.07 | Upgrade
|
| Total Current Liabilities | 9.28 | 4.95 | 3.69 | 2.8 | 2.22 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | -0 | -0 | Upgrade
|
| Total Liabilities | 9.28 | 4.95 | 3.69 | 2.8 | 2.22 | Upgrade
|
| Common Stock | 1.48 | 1.23 | 1.16 | 1.03 | 0.84 | Upgrade
|
| Additional Paid-In Capital | 89.72 | 68.89 | 64.86 | 59.39 | 52.49 | Upgrade
|
| Retained Earnings | -71.91 | -61.46 | -60.36 | -44.11 | -24.73 | Upgrade
|
| Comprehensive Income & Other | - | - | 0 | 0.47 | 0.56 | Upgrade
|
| Shareholders' Equity | 19.29 | 8.66 | 5.66 | 16.78 | 29.15 | Upgrade
|
| Total Liabilities & Equity | 28.57 | 13.6 | 9.35 | 19.57 | 31.37 | Upgrade
|
| Net Cash (Debt) | 23.49 | 6.09 | 3.32 | 15.43 | 11.95 | Upgrade
|
| Net Cash Growth | 285.70% | 83.49% | -78.50% | 29.13% | 1224.40% | Upgrade
|
| Net Cash Per Share | 1.42 | 0.39 | 0.25 | 1.32 | 1.17 | Upgrade
|
| Filing Date Shares Outstanding | 18.63 | 15.35 | 14.46 | 12.91 | 11.57 | Upgrade
|
| Total Common Shares Outstanding | 18.63 | 15.35 | 14.46 | 12.91 | 11.57 | Upgrade
|
| Working Capital | 16.09 | 5.7 | 3.77 | 14.89 | 10.21 | Upgrade
|
| Book Value Per Share | 1.04 | 0.56 | 0.39 | 1.30 | 2.52 | Upgrade
|
| Tangible Book Value | 19.29 | 8.66 | 5.66 | 16.78 | 29.15 | Upgrade
|
| Tangible Book Value Per Share | 1.04 | 0.56 | 0.39 | 1.30 | 2.52 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.